VentriPoint Diagnostics Ltd. (CVE:VPT – Get Free Report) Director Robert Hodgkinson acquired 75,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was acquired at an average price of C$0.21 per share, with a total value of C$15,900.00.
Robert Hodgkinson also recently made the following trade(s):
- On Thursday, April 18th, Robert Hodgkinson acquired 36,500 shares of VentriPoint Diagnostics stock. The stock was acquired at an average price of C$0.21 per share, with a total value of C$7,774.50.
VentriPoint Diagnostics Trading Up 4.8 %
Shares of VPT stock opened at C$0.22 on Wednesday. VentriPoint Diagnostics Ltd. has a 52-week low of C$0.12 and a 52-week high of C$0.36. The stock has a market cap of C$34.50 million, a price-to-earnings ratio of -7.33 and a beta of 0.39. The company has a debt-to-equity ratio of 32.61, a quick ratio of 6.67 and a current ratio of 2.06. The firm has a fifty day moving average of C$0.25 and a 200-day moving average of C$0.24.
About VentriPoint Diagnostics
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements.
See Also
- Five stocks we like better than VentriPoint Diagnostics
- Investing in Travel Stocks Benefits
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Invest in Blue Chip Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for VentriPoint Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VentriPoint Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.